In rare cases, a person might have acoustic tumors (also called vestibular schwannoma) on both sides (bilateral). This is the hallmark of a disease called neurofibromatosis Type II (NF2). The incidence of NF2 is one in 33,000 to 40,000 live births. Early diagnosis using gadolinium-enhanced MRI and techniques of hearing preservation surgery have improved our ability to prevent total hearing loss while completely removing the tumors. As this is a genetic disease, with a dominant inheritance pattern, family screening and DNA analysis have helped early diagnosis.
Half of individuals with neurofibromatosis Type II (NF2) have inherited the disorder from an affected parent, and half seem to have a mutation for the first time in their family. Each child of an affected parent has a 50% chance of inheriting the disorder.
Unlike those with a unilateral vestibular schwannoma, people with NF2 usually get symptoms in their teens or early adulthood. They frequently also develop multiple brain and spinal cord tumors. NF2 tumors may affect the nerves important for swallowing, speech, eye and facial movement, and facial sensation.
At House Clinic, treatment options offered for NF2 include: (1) hearing preservation surgery with total tumor removal, (2) observation (“watchful waiting”) without surgical intervention, (3) surgical ‘decompression’ of the tumor without totaling removing it, (4) retrosigmoid surgery, with partial tumor removal, (5) translabyrinthine total tumor removal which will not preserve any hearing, and (6) auditory brainstem or cochlear implantation. For people with larger tumors or no useful hearing, the auditory brainstem implant (ABI) allows restoration of some auditory function when the tumor is removed. In selected cases, a cochlear implant can be used, with good results.